A COVID19 vaccine update.
As announced by Russia president Vladimir Putin, sputnik V is called to be the COVID19 vaccine developed in Russia by the Gamaleya Institute of Epidemiology and Microbiology along with RDIF.
Currently, the vaccine has not been tested for clinical 3 trial phase. This vaccine has been until now the world’s first vaccine which has completed its second trial phase. This COVID19 vaccine may work ‘effective’ and ‘stable community’ against this disease.
CEO of the Russian Direct Investment Fund (RDIF) said on Thursday, The production of vaccines is a very important issue. Currently, we are looking for a partnership with India.
They further said, “ We planning to produce the vaccine in more than 5 countries and there is a high demand for the vaccine from Asia, Latin America, Italy, and other parts of the world regarding the delivery of the vaccine.”
Around 20,000 people have taken place in clinical trials of the vaccine.
Sputnik V vaccine consists of 2 shots of different versions of human adenovirus, different virus types. It is made using two types of human adenovirus serotypes: number 5 (Ad 5) and number 26(Ad 26) has a clear advantage over the one vector type.
In an online press briefing, Kirill Dmitriev, CEO, Russian Direct Investment Fund (RDIF) said
“The production of the vaccine is a very important issue. Currently, we are looking for a partnership with India. We believe that they are capable of producing the Gamaleya vaccine and it is very important to say that those partnerships to produce the vaccine will enable us to cover the demand that we have,”
He added “We are going to do clinical trials not just in Russia but also in the UAE, Saudi Arabia, probably in Brazil and India. We are planning to produce the vaccine in more than five countries and there is a very high demand from Asia, Latin America, Italy and other parts of the world regarding the delivery of the vaccine,”